Gland Pharma schedules 48th AGM for Aug 25, 2026 via VC
Gland Pharma Limited will hold its 48th AGM on August 25, 2026, via VC/OAVM. Shareholders must register email IDs to receive FY26 financial statements and AGM notices electronically, as physical copies will not be dispatched. Compliance with SEBI’s Third Amendment Regulations 2024 mandates digital dissemination, requiring physical shareholders to update KYC details with MUFG Intime India Private Limited to access documents and vote.
*this image is generated using AI for illustrative purposes only.
Gland Pharma Limited has scheduled its 48th Annual General Meeting (AGM) for Tuesday, August 25, 2026, at 11:00 A.M. IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM), in compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and various Ministry of Corporate Affairs (MCA) circulars. This virtual format ensures shareholder participation without physical presence, with the deemed venue fixed at the company’s corporate office in Hyderabad.
The company notified BSE Limited and National Stock Exchange of India Limited on July 28, 2026, regarding the newspaper advertisements published in English and Telugu media. These disclosures were made pursuant to Regulation 47 of the SEBI Listing Regulations. Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the communication, confirming the adherence to regulatory timelines and disclosure norms.
Key Meeting Details
| Parameter | Detail |
|---|---|
| Meeting Date | August 25, 2026 |
| Time | 11:00 A.M. IST |
| Mode | Video Conferencing / OAVM |
| Deemed Venue | Corporate Office, Hyderabad |
| Quorum Basis | Section 103 of Companies Act, 2013 |
Shareholders attending via VC/OAVM will be counted for reckoning the quorum under Section 103 of the Companies Act, 2013. The live webcast of the AGM will be provided by NSDL at www.evoting.nsdl.com , allowing members to view proceedings remotely.
Document Access and KYC Compliance
In alignment with the SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, Gland Pharma will dispatch the Notice of AGM, Standalone and Consolidated Financial Statements for FY26, Board’s Report, and Auditor’s Report only via electronic mode. Physical copies will not be sent to members who have not registered their email addresses with the Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited, or with Depositories.
Members holding shares in physical mode or those without registered email IDs must update their details to access these documents. A letter containing a weblink and/or QR Code will be sent to shareholders who have not registered email IDs, enabling them to access the AGM notice and Annual Report online.
Action Required by Shareholders
- Physical Shareholders: Must submit request forms with supporting documents to MUFG Intime India Private Limited at C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai – 400 083.
- Demat Shareholders: Should update email IDs and KYC details with their respective Depository Participants.
- KYC Deadline Impact: As per SEBI Master Circular dated May 7, 2024, physical shareholders who have not completed PAN, contact details, bank account details, and specimen signature by April 1, 2024, can only lodge grievances or receive dividends after furnishing these details and nomination.
AGM documents will also be available on the company’s website ( www.glandpharma.com ), BSE Limited ( www.bseindia.com ), NSE India ( www.nseindia.com ), and NSDL ( www.evoting.nsdl.com ). Members are urged to review remote e-voting instructions detailed in the AGM Notice to cast their votes effectively.
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.05% | -1.25% | +2.33% | +44.90% | +18.32% | -37.17% |
How might Gland Pharma's FY26 financial results, to be presented at the AGM, influence investor sentiment regarding its post-acquisition integration strategy?
What specific operational or regulatory challenges could impact Gland Pharma's ability to meet its growth targets in the US generic drug market for the upcoming fiscal year?
Will the shift to fully electronic document distribution significantly improve shareholder engagement metrics and voting participation rates compared to previous years?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
